The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human

Recruiting

• Conditions: Coronary Heart Disease, Susceptibility to, 1

• Registration Number: NCT05945394
• Lead Sponsor: Nanjing Medical University

Brief Summary

To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human

Detailed Description

Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated.

Study Timeline

• Study First Submitted: 2023-06-29
• Study First Submitted QC: 2023-07-13
• Study First Posted: 2023-07-14
• Status Verified: 2023-09
• Study Start: 2023-09-01
• Last Update Submitted: 2023-09-08
• Last Update Posted: 2023-09-13
• Primary Completion: 2023-10-31
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

1. Patients with suspected coronary heart disease
2. patients received coronary angiography

Exclusion Criteria

1. NYHA III-IV
2. malignant tumor
3. acute infection
4. thyroid dysfunction

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
stenosis of coronary artery	1 week	The stenosis of coronary artery based on the results of coronary angiography

Secondary Outcome Measures

Name	Time	Method
coronary artery calcium	1 week	The coronary artery calcification based on the results of coronary angiography

Trial Locations

Locations (1)

Huai'an First People's Hospital; 🇨🇳 Huai'an, Jiangsu, China